COVID-19 Vaccine Booster doses
The CDC analyzed surveillance data from 12,591 patients enrolled in V-Safe, who received a booster vaccination of the Pfizer-BioNTech COVID-19, vaccine and found the occurrence of adverse events to be similar to ADR experienced after the second dose.
A study analyzing the antibody levels produced with the Pfizer-BioNTech and Moderna COVID-19 vaccines, in 167 adults, found the Pfizer-BioNTech elicited lower antibody titers in patients 50 years and older compared to patients less than 50 years. Antibody titers were also lower in age-similar peers compared to Moderna vaccine recipients. There were no differences in antibody levels between older and younger patients that received the Moderna vaccine. This study did not measure neutralizing antibodies.
A case-control study involving 105,446 pregnancies, from eight large U.S. healthcare systems and an analysis of outcomes from 2,456 women enrolled in a CDC pregnancy registry found no increase in the risk for spontaneous abortion with COVID-19 vaccinations.
In a 32,449 patient, Phase III, trial (NCT04516746), two doses of AstraZeneca’s COVID-19 vaccine, given 4-weeks apart, had efficacy of 74% overall and 83.5% in patients 65 years and older. Efficacy was defined as prevention of symptomatic COVID-19.
In a 29-day, 4,180 patient, Phase III trial (NCT04425629), 1% of patients treated with 1,200 mg of the combination of casirivimab with imdevimab progressed to hospitalization or death compared to 3.2% with placebo in high-risk COVID-19 outpatients. Treatment with 2,400 mg of the monoclonal combination resulted in 1.3% of patients progressing to hospitalization or death compared to 4.6% with placebo.
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker